云开药网品牌怎么样 申请店铺

我要投票 云开药网在网上药店行业中的票数:20 更新时间:2024-11-21
云开药网是哪个国家的品牌?「云开药网」是 浙江云开亚美大药房连锁有限公司 旗下著名品牌。该品牌发源于浙江,由创始人刘云江在2012-01-05期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
云开药网怎么样

浙江云开亚美医药科技股份有限公司(以下简称云开亚美),成立于2011年,上市公司海正药业(股票代码600267)控股企业。是国内领先的重大慢性疾病用药连锁专科药房,旗下有浙江云开亚美大药房连锁有限公司、上海云开亚美大药房有限公司、上海医度迅健康咨询有限公司三大子公司,以经营专科药品为特色,是一家集网上药店、高端连锁、专业药师服务为一体的优秀的医药电商企业,志于打造成为中国专业的医药电子商务零售平台。

云开亚美作为一个针对重大慢性疾病用药的高端零售品牌,专营重大慢特疾病用药及产品(包括药品,保健品,医疗器械等),并基于强大的数据库管理能力和专业的药师服务团队,致力于为客户提供持续、专业的疾病管理服务。

从建立以来,云开亚美一直专注于重大慢性特殊疾病领域,专营慢特疾病用药及产品(包括药品,保健品,医疗器械等),并以专业的医药学知识和真诚服务,基于患者数据库管理,致力于为客户提供持续、专业的疾病管理服务,以人为本的服务理念获得顾客信赖。

所有药师都具有药学专业资格证书,其中拥有执业药师资格占30%,具有扎实的医药基础、优秀的职业素养并在各自领域积累了特有的丰富专科用药知识和经验,致力于提供专业、专精的服务

数十位专业药师免费在线咨询,量身定做电子药历,全程指导用药,并在饮食、运动、日常保健注意等方面给以合理、贴心的专业指导。不仅保证患者可以坚持正确的用药过程,在日常生活各个方面也是遵照科学的方法给予指导,帮助患者全面保持健康。

截止2016年6月,云开亚美已在互联网全渠道建设部署,包括自建交易电商平台(云开药网|无线网店|云开掌上药店APP)、第三方平台旗舰店(天猫、京东、一号店、818、八百方、京卫药房网等)、社交交易平台(微信交易账户网店、支付宝服务窗交易账号网店等),已形成了良好的口碑效应

云开亚美积累了近40种慢特疾病近2000万的慢特疾病患者数据,尤其在股骨头坏死、糖尿病、慢性肾病、慢性肝病等领域极具优势。

云开亚美采用独有的DTC(DirectToConsumer)患教平台,面向慢性特殊疾病终端患者,以数以千万级的详实的患者数据库为核心,通过DTC网站、呼叫中心、短信平台、直邮平台、患者俱乐部及网络互动六大信息沟通渠道,为患者提供国际领先的疾病贴身服务。

专业IT技术团队20人,自建独立订单系统EC-ERP、专业客服接待/呼叫系统、CRM用户管理系统、大型专业物流仓储系统,系统自动跟踪订单、管理后台数据化呈现,用户全程实时跟踪更清晰、更直观、更简单。


Zhejiang Yunkai Yamei Pharmaceutical Technology Co., Ltd. (hereinafter referred to as Yunkai Yamei), founded in 2011, is a holding enterprise of Haizheng Pharmaceutical (Stock Code: 600267). It is a leading chain specialty pharmacy for major chronic diseases in China. It has three subsidiaries, namely Zhejiang Yunkai Yamei pharmacy chain Co., Ltd., Shanghai Yunkai Yamei pharmacy Co., Ltd. and Shanghai yiduxun Health Consulting Co., Ltd. It is an excellent pharmaceutical e-commerce enterprise integrating online pharmacy, high-end chain and professional pharmacist services with the characteristics of specialized drugs The company aims to build a professional pharmaceutical e-commerce retail platform in China. As a high-end retail brand for major chronic disease drugs, Yunkai Yamei specializes in major chronic disease drugs and products (including drugs, health products, medical devices, etc.), and is committed to providing customers with continuous and professional disease management services based on strong database management ability and professional pharmacist service team. Since its establishment, Yunkai Yamei has been focusing on the field of major chronic special diseases, specializing in drugs and products for chronic special diseases (including drugs, health care products, medical devices, etc.), providing continuous and professional disease management services for customers based on professional medical knowledge and sincere service, patient database management, and people-oriented service concept to win customers' trust 。 All pharmacists have pharmaceutical professional qualification certificates, of which 30% are licensed pharmacists. They have solid medical foundation, excellent professional quality and have accumulated unique and rich specialized drug knowledge and experience in their respective fields. They are committed to providing professional and professional services for dozens of professional pharmacists, free online consultation, customized electronic drug calendar, guiding drug use in the whole process, and drinking Food, sports, daily health care and other aspects to give reasonable and thoughtful professional guidance. Not only to ensure that patients can adhere to the correct medication process, in all aspects of daily life is also in accordance with scientific methods to give guidance to help patients to maintain overall health. As of June 2016, Yun Kai Asia and the United States have already deployed in the whole channel of the Internet, including self built trading platform (cloud pharmaceutical network, wireless Internet store, cloud open pocket pharmacy APP), third party platform flagship store (Tmall, Jingdong, No. 1 store, 818, eight hundred party, Jingwei pharmacy network, etc.), social trading platform (WeChat trading account shop, Alipay service window, transaction account shop, etc.) It has formed a good word-of-mouth effect. Yunkai Yamei has accumulated data of nearly 20 million patients with 40 kinds of chronic diseases, especially in the areas of femoral head necrosis, diabetes, chronic kidney disease, chronic liver disease and so on. Yunkai Yamei adopts the unique DTC (directtoconsumer) patient education platform for the terminal patients with chronic special diseases. With tens of millions of detailed patient databases as the core, it provides the patients with the world's leading disease intimate service through six information communication channels: DTC website, call center, SMS platform, direct mail platform, patient club and network interaction. There are 20 professional IT technical teams, with independent order system EC-ERP, professional customer service reception / call system, CRM user management system and large-scale professional logistics storage system. The system automatically tracks orders and manages the background data presentation. The real-time tracking of users is clearer, more intuitive and simpler.

本文链接: https://brand.waitui.com/30598aa74.html 联系电话:057181909763

千城特选小程序码

7×24h 快讯

拼多多:第三季度营收增速环比下降,将坚定高质量发展战略应对竞争挑战

36氪获悉,拼多多发布2024年第三季度财报。财报显示,本季度拼多多营收达到994亿元,与上个季度相比,营收的增速有所放缓。业内分析认为,一方面是因为电商行业的竞争依然激烈,另一方面是平台的“百亿减免”等举措影响了短期的财报表现。“为了应对行业竞争,我们将坚定地执行高质量发展战略,继续实行‘减免+扶持’的举措,持续完善平台及产业生态,为供需两侧带来更大的普惠。”拼多多陈磊表示。

2小时前

拼多多:第三季度利润环比下降22%,将长期投入“新质供给”“电商西进”战略

36氪获悉,拼多多发布2024年第三季度财报。财报显示,本季度拼多多利润达到250亿元,环比下降22%。过去这个季度,拼多多先后推出“百亿减免”“电商西进”“新质商家扶持计划”等重磅举措,持续扩大对生态建设的投资,一定程度上影响了短期的财报表现。拼多多陈磊表示,在财务数据之外,我们更加看重生态投资带来的长期价值,未来几个季度,拼多多将继续投入“新质供给”“电商西进”等战略,给用户、商家及产业带来更长远的回报。

2小时前

莎普爱思:股东拟合计减持不超5%公司股份

36氪获悉,莎普爱思公告,股东陈德康持有公司12.39%股份,上海景兴实业投资有限公司持有公司4.7%股份。陈德康计划减持公司股份数量合计不超过758.32万股,即不超过公司总股本的2%。上海景兴计划减持公司股份数量合计不超过1137.48万股,即不超过公司总股本的3%。

2小时前

永杰新材上交所主板IPO申请获证监会同意注册批复

36氪获悉,证监会下发关于同意永杰新材料股份有限公司首次公开发行股票注册的批复,同意该公司首次公开发行股票的注册申请。根据招股书,该公司拟在上交所主板上市,公司专业从事铝板带箔的研发、生产与销售,产品主要包括铝板带和铝箔两大类。

2小时前

东方电缆:公司及子公司近期中标合计约40亿元海底电缆项目

36氪获悉,东方电缆公告,公司及全资子公司东方海工院近期收到相关通知书,确认公司及东方海工院联合体为相关项目中标人。其中,直流海底电缆项目中标金额约15.14亿元,交流海底电缆项目中标金额合计约24.72亿元,以上项目合计中标金额约40亿元。同日公告,公司拟以自有资金投资建设东方中央研究院·总部项目,项目总投资金额约为5.54亿元。

2小时前

本页详细列出关于360好药的品牌信息,含品牌所属公司介绍,360好药所处行业的品牌地位及优势。
咨询